Mary Tagliaferri - Mar 12, 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Stock symbol
YMAB
Transactions as of
Mar 12, 2024
Transactions value $
$0
Form type
4
Date filed
3/14/2024, 05:01 PM
Previous filing
Mar 8, 2024
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +4.66K $0.00 4.66K Mar 12, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Stock Option (right to buy) Award $0 +27.9K $0.00 27.9K Mar 12, 2024 Common Stock 27.9K $16.09 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 4,660 restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting date of the RSUs. The RSUs vest in equal quarterly installments over a three-year period measured from three months following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F3 The stock option shall vest and become exercisable in equal monthly installments over a three-year period measured from one month following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date.